European Journal of Pharmacology: Molecular Pharmacology
Regular paperCharacterization of the human dopamine D3 receptor expressed in transfected cell lines
References (23)
- et al.
Coupling of D2 and D3 dopamine receptors to G-proteins
FEBS Lett.
(1993) - et al.
A ternary complex model explains the agonist-specific binding properties of the adnylate cyclase-coupled β-adrenergic receptor
J. Biol. Chem.
(1980) - et al.
A mutation-induced activated state of the β2-adrenergic receptor
J. Biol. Chem.
(1993) - et al.
Stable expression of human D3 dopamine receptors in GH4C1 pituitary cells
FEBS Lett.
(1992) - et al.
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor
Eur. J. Pharmacol.
(1992) - et al.
Dopamine D1 receptor stimulation of cyclic AMP accumulation in COS-1 cells
Eur. J. Pharmacol.
(1991) - et al.
Differential coupling of dopaminergic D2 receptors expressed in different cell types
J. Biol. Chem.
(1990) - et al.
Changes in the level of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides
Biochem. J.
(1983) - et al.
Expression and characterization of the rat D3 dopamine receptor: pharmacologic properties and development of antibodies
J. Pharmacol. Exp. Ther.
(1993) - et al.
High-efficiency transformation of mammalian cells by plasmid DNA
Mol. Cell. Biol.
(1987)
A transduction pathway associated with receptors coupled to the inhibitory guanine nucleotide binding protein Gi that amplifies ATP-mediated arachidonic acid release
Cited by (108)
Analgesia and pain: Dual effect of dopamine on the peripheral nociceptive system is dependent on D<inf>2</inf>-or D<inf>1</inf>–like receptor activation
2022, European Journal of PharmacologyCitation Excerpt :This event suggests differences in intracellular signalling mediated by each type of receptor, such as the level of inhibition of the adenylate cyclase enzyme. For example, D3 receptors do not or weakly inhibit adenylate cyclase enzyme, depending on the type of cell line evaluated, as reported in some previous studies (Chio et al., 1994; Freedman et al., 1994; MacKenzie et al., 1994; Tang et al., 1994; Robinson and Caron, 1996). Although dopamine D1-like receptors are expressed in greater quantities than D2-like receptors, these have high affinity and are activated by lower concentrations of dopamine (Paulus and Trenkwalder, 2006).
Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent
2015, Bioorganic and Medicinal ChemistryCitation Excerpt :Displacement of [3H]-SCH23 390, [3H]-prazosin, [3H]-RX 821 002 and [3H]-4-DAMP evaluated in CHO cells which stably expressed the human D1, α1, α2C and M3 receptors. In case of human 5-HT6/7 and D2/3/4 receptors stably expressed in CHO cells, [3H]-LSD and [3H]-methyl-spiperone were used, respectively.20–22 The in vitro functional activity of two selected compounds 10 and 14 on intracellular cAMP/IP1/Ca2+ release levels, studied in CHO or HEK-293 cells which stably expressed the human 5-HT1A/2A/2C/6/7, α1/2C, H1 and D1/2/3/4 receptors, was determined at Cerep (Le Bois l’Eveque, 86600 Celle L’Evescault, France) according to the previously published methods (Table 3).20–23